Project Grant HT94252510805

Award Date 9/15/25
Completion Date 9/14/28
Dollars Obligated $565K
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
The Department of Defense's Defense Health Agency awarded a $700,032 Project Grant to Duke University under the Military Medical Research and Development (CFDA 12.420) program. The grant, effective August 1, 2025 through July 31, 2029, will fund research to investigate "Imaging Strategies and Biomarkers for Detecting the Metabolic Interplay of Glutamine and Aspartate in RCC." This research aims to transform healthcare for military service members, veterans, and the broader public by...
This $240,897 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, will support integrative transcriptomic and epigenomic profiling of subependymal giant cell astrocytoma at single-cell resolution. The award was made to Duke University's Office of Research Administration on August 1, 2025, with a period of performance through July 31, 2027. The Military Medical Research and Development program funds advanced biomedical...
The Defense Health Agency awarded Duke University a $402,500 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period of June 1, 2023 through May 31, 2025. The grant will support Duke University's research efforts to target the ferropotosis protection mechanism of serum to disable cancer metastasis. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions for both...
The U.S. Department of Defense's Defense Health Agency awarded a $845,250 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Duke University. The grant, with a performance period from July 1, 2025 to June 30, 2028, will fund research to engineer TCR-T cells to target human endogenous retroviruses for non-small cell lung cancer immunotherapy. The goal of this advanced biomedical research is to transform healthcare for military service members, veterans, and...
The Defense Health Agency awarded a $828,591 Project Grant under CFDA 12.420, the Military Medical Research and Development program, to Duke University. The grant supports research titled "Targeting the Tumor Microenvironment to Enhance Immunotherapy for SCLC", with a performance period from May 1, 2025 to April 30, 2027. This research aims to transform healthcare for military service members, veterans, and the public by advancing innovative biomedical investigations focused on...
The Department of Defense's Defense Health Agency awarded a $241,500 Project Grant to Duke University under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on September 1, 2025, supports research to understand the molecular communication between different types of prostate cancer cells. This fundamental research, to be conducted at Duke University in Durham, North Carolina, aims to transform healthcare for military service members, veterans, and the...
The Department of Defense's Defense Health Agency awarded a $4,818,759 Project Grant to Duke University under the Military Medical Research and Development program (CFDA 12.420) for the project "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant, awarded on April 1, 2024, will fund research to improve understanding and treatment of lethal breast cancers through advanced single-cell and spatial analysis techniques. This work supports the program's goals of...
The federal Project Grant award of $161,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Duke University to investigate breast cancer brain metastases. The research aims to integrate immunogenomic and phenotypic vulnerabilities to improve outcomes for this challenging condition. The award period runs from April 1, 2025 to March 31, 2026. This grant is part of the Defense Health Agency's strategic...
The Defense Health Agency awarded Duke University a $1,167,250 Project Grant (CFDA 12.420 - Military Medical Research and Development) with a performance period from June 1, 2024 to May 31, 2027. The grant funding supports Duke's research on the role of the NLRP3-NLRC5 signaling pathway in melanoma immune evasion and dormancy. The research aims to advance the understanding of mechanisms underlying melanoma progression, with the potential to inform new therapeutic approaches. As a prominent...
The U.S. Defense Health Agency awarded a $1,449,000 Project Grant to Duke University to conduct research aimed at "Identifying Essential Molecular Mechanisms for Advanced Prostate Cancer Growth by a New Chemical Compound." This grant is funded under the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The...

This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $564,705.00 to Duke University to conduct research on identifying "oncofusion-interacting proteins as essential drug targets for common and rare oncofusions in rhabdomyosarcoma." The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical investigations in cancer research. The grant has a performance period from September 15, 2025 to September 14, 2028. This award demonstrates the Defense Health Agency's strategic approach to funding sophisticated medical research across diverse domains to address critical health challenges relevant to the military.

Generated 8/5/25, 3:56 AM